<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="drugDebug/PMC7118659/results/search/disease/results.xml">
  <result pre="- including this research content - immediately available in PubMed" exact="Central" post="and other publicly funded repositories, such as the WHO"/>
  <result pre="Central and other publicly funded repositories, such as the WHO" exact="COVID" post="database with rights for unrestricted research re-use and analyses"/>
  <result pre="Abstract Recently, a novel coronavirus (2019-nCoV), officially known as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite"/>
  <result pre="Recently, a novel coronavirus (2019-nCoV), officially known as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic"/>
  <result pre="a novel coronavirus (2019-nCoV), officially known as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), emerged in China. Despite drastic containment"/>
  <result pre="this virus is ongoing. SARS-CoV-2 is the aetiological agent of" exact="coronavirus disease" post="2019 (COVID-19) characterised by pulmonary infection in humans. The"/>
  <result pre="virus is ongoing. SARS-CoV-2 is the aetiological agent of coronavirus" exact="disease" post="2019 (COVID-19) characterised by pulmonary infection in humans. The"/>
  <result pre="the aetiological agent of coronavirus disease 2019 (COVID-19) characterised by" exact="pulmonary" post="infection in humans. The efforts of international health authorities"/>
  <result pre="aetiological agent of coronavirus disease 2019 (COVID-19) characterised by pulmonary" exact="infection" post="in humans. The efforts of international health authorities have"/>
  <result pre="counter the most severe effects of the disease. In the" exact="absence of" post="a known efficient therapy and because of the situation"/>
  <result pre="to Peru and was the previous drug of choice against" exact="malaria" post="[3]. For decades, chloroquine was a front-line drug for"/>
  <result pre="was a front-line drug for the treatment and prophylaxis of" exact="malaria" post="and is one of the most prescribed drugs worldwide"/>
  <result pre="the indication for chloroquine was a high dose for a" exact="short" post="period of time (due to its toxicity at high"/>
  <result pre="Hydroxychloroquine was reported to be as active as chloroquine against" exact="Plasmodium falciparum malaria" post="and less toxic, but it is much less active"/>
  <result pre="reported to be as active as chloroquine against Plasmodium falciparum" exact="malaria" post="and less toxic, but it is much less active"/>
  <result pre="strains [5]. Chloroquine is also utilised in the treatment of" exact="autoimmune" post="diseases [6]. Yet the activity of the molecule is"/>
  <result pre="diseases [6]. Yet the activity of the molecule is not" exact="limited" post="to malaria and the control of inflammatory processes, as"/>
  <result pre="Yet the activity of the molecule is not limited to" exact="malaria" post="and the control of inflammatory processes, as illustrated by"/>
  <result pre="its broad-spectrum activity against a range of bacterial, fungal and" exact="viral" post="infections [7], [8], [9], [10]. Indeed, in the mid-1990s,"/>
  <result pre="broad-spectrum activity against a range of bacterial, fungal and viral" exact="infections" post="[7], [8], [9], [10]. Indeed, in the mid-1990s, due"/>
  <result pre="and immunomodulatory properties [11], chloroquine repurposing was explored against human" exact="immunodeficiency" post="virus (HIV) and other viruses associated with inflammation and"/>
  <result pre="seventh human coronavirus described to date as being responsible for" exact="respiratory" post="infection. Evidence was rapidly reported that patients were suffering"/>
  <result pre="Evidence was rapidly reported that patients were suffering from an" exact="infection" post="with a novel Betacoronavirus tentatively named 2019 novel coronavirus"/>
  <result pre="measures, the spread of 2019-nCoV, now officially known as severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2), is ongoing. Phylogenetic analysis"/>
  <result pre="the spread of 2019-nCoV, now officially known as severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2), is ongoing. Phylogenetic analysis of"/>
  <result pre="spread of 2019-nCoV, now officially known as severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2), is ongoing. Phylogenetic analysis of this"/>
  <result pre="attention for repurposing this drug in the therapy of the" exact="disease" post="caused by SARS-CoV-2, named coronavirus disease 2019 (COVID-19). 2"/>
  <result pre="in the therapy of the disease caused by SARS-CoV-2, named" exact="coronavirus disease" post="2019 (COVID-19). 2 Antiviral properties of chloroquine In vitro,"/>
  <result pre="the therapy of the disease caused by SARS-CoV-2, named coronavirus" exact="disease" post="2019 (COVID-19). 2 Antiviral properties of chloroquine In vitro,"/>
  <result pre="to possess antiviral activity against RNA viruses as diverse as" exact="rabies" post="virus [16], poliovirus [17], HIV [12,[18], [19], [20], hepatitis"/>
  <result pre="as rabies virus [16], poliovirus [17], HIV [12,[18], [19], [20]," exact="hepatitis" post="A virus [21,22], hepatitis C virus [23], influenza A"/>
  <result pre="poliovirus [17], HIV [12,[18], [19], [20], hepatitis A virus [21,22]," exact="hepatitis" post="C virus [23], influenza A and B viruses [24],"/>
  <result pre="influenza A H5N1 virus [28], Chikungunya virus [29], [30], [31]," exact="Dengue" post="virus [32,33], Zika virus [34], Lassa virus [35], Hendra"/>
  <result pre="virus [39], as well as various DNA viruses such as" exact="hepatitis" post="B virus [40] and herpes simplex virus [41].The antiviral"/>
  <result pre="various DNA viruses such as hepatitis B virus [40] and" exact="herpes" post="simplex virus [41].The antiviral properties of chloroquine described in"/>
  <result pre="reported to inhibit in vitro the replication of HCoV-229E in" exact="epithelial" post="lung cell cultures [43,44]. In 2009, it was reported"/>
  <result pre="cell cultures [43,44]. In 2009, it was reported that lethal" exact="infections" post="of newborn mice with the HCoV-O43 coronavirus could be"/>
  <result pre="Although chloroquine was reported to be active against Middle East" exact="respiratory" post="syndrome coronavirus (MERS-CoV) in vitro [46], this observation remains"/>
  <result pre="chloroquine was reported to be active against Middle East respiratory" exact="syndrome" post="coronavirus (MERS-CoV) in vitro [46], this observation remains controversial"/>
  <result pre="sense in a situation of a public-health emergency and the" exact="absence of" post="any known efficient therapy to investigate the possible effect"/>
  <result pre="SARS-CoV-2 infections. Although the long use of this drug in" exact="malaria" post="therapy demonstrates the safety of acute chloroquine administration to"/>
  <result pre="of this drug in malaria therapy demonstrates the safety of" exact="acute" post="chloroquine administration to humans, one cannot ignore the minor"/>
  <result pre="cumulative dose [52], and the existence of some reports on" exact="cardiomyopathy" post="as a severe adverse effect caused by chloroquine [53,54]."/>
  <result pre="the best available candidates to impact the severity of SARS-CoV-2" exact="infections" post="in humans. Currently, at least ten clinical trials are"/>
  <result pre="pathogen studied. Chloroquine can inhibit a pre-entry step of the" exact="viral" post="cycle by interfering with viral particles binding to their"/>
  <result pre="a pre-entry step of the viral cycle by interfering with" exact="viral" post="particles binding to their cellular cell surface receptor. Chloroquine"/>
  <result pre="stage of virus replication by interfering with the pH-dependent endosome-mediated" exact="viral" post="entry of enveloped viruses such as Dengue virus or"/>
  <result pre="the pH-dependent endosome-mediated viral entry of enveloped viruses such as" exact="Dengue" post="virus or Chikungunya virus [60,61]. Due to the alkalisation"/>
  <result pre="in endosomes at acidic pH results in fusion of the" exact="viral" post="and endosomal membranes leading to the release of the"/>
  <result pre="viral and endosomal membranes leading to the release of the" exact="viral" post="SARS-CoV-1 genome into the cytosol [63]. In the absence"/>
  <result pre="the viral SARS-CoV-1 genome into the cytosol [63]. In the" exact="absence of" post="antiviral drug, the virus is targeted to the lysosomal"/>
  <result pre="low pH, along with the action of enzymes, disrupts the" exact="viral" post="particle, thus liberating the infectious nucleic acid and, in"/>
  <result pre="action of enzymes, disrupts the viral particle, thus liberating the" exact="infectious" post="nucleic acid and, in several cases, enzymes necessary for"/>
  <result pre="cases, enzymes necessary for its replication [64]. Chloroquine-mediated inhibition of" exact="hepatitis" post="A virus was found to be associated with uncoating,"/>
  <result pre="[22]. Chloroquine can also interfere with the post-translational modification of" exact="viral" post="proteins. These post-translational modifications, which involve proteases and glycosyltransferases,"/>
  <result pre="flavivirus prM protein to M protein [32]. As a result," exact="viral" post="infectivity is impaired. In the herpes simplex virus (HSV)"/>
  <result pre="[32]. As a result, viral infectivity is impaired. In the" exact="herpes" post="simplex virus (HSV) model, chloroquine inhibited budding with accumulation"/>
  <result pre="pH modulation by chloroquine can impair the proper maturation of" exact="viral" post="protein [32] and the recognition of viral antigen by"/>
  <result pre="proper maturation of viral protein [32] and the recognition of" exact="viral" post="antigen by dendritic cells, which occurs through a Toll-like"/>
  <result pre="and the enhancement of human cytotoxic CD8+ T-cell responses against" exact="viral" post="antigens [70]. In the influenza virus model, it was"/>
  <result pre="clinical applications of this drug in inflammatory diseases such as" exact="rheumatoid arthritis" post="[74], [75], [76], lupus erythematosus [6,77] and sarcoidosis [78]."/>
  <result pre="applications of this drug in inflammatory diseases such as rheumatoid" exact="arthritis" post="[74], [75], [76], lupus erythematosus [6,77] and sarcoidosis [78]."/>
  <result pre="in inflammatory diseases such as rheumatoid arthritis [74], [75], [76]," exact="lupus erythematosus" post="[6,77] and sarcoidosis [78]. Chloroquine inhibits interleukin-1 beta (IL-1β)"/>
  <result pre="as rheumatoid arthritis [74], [75], [76], lupus erythematosus [6,77] and" exact="sarcoidosis" post="[78]. Chloroquine inhibits interleukin-1 beta (IL-1β) mRNA expression in"/>
  <result pre="in U937 monocytic cells treated with chloroquine [84]. In the" exact="Dengue" post="virus model, chloroquine was found to inhibit interferon-alpha (IFNα),"/>
  <result pre="virion assembly and budding (Fig. 1 ). Finally, in COVID-19" exact="disease" post="this drug could act indirectly through reducing the production"/>
  <result pre="representation of the possible effects of chloroquine on the severe" exact="acute" post="respiratory syndrome coronavirus 2 (SARS-CoV-2) replication cycle. SARS-CoV2, like"/>
  <result pre="of the possible effects of chloroquine on the severe acute" exact="respiratory" post="syndrome coronavirus 2 (SARS-CoV-2) replication cycle. SARS-CoV2, like other"/>
  <result pre="the possible effects of chloroquine on the severe acute respiratory" exact="syndrome" post="coronavirus 2 (SARS-CoV-2) replication cycle. SARS-CoV2, like other human"/>
  <result pre="(E) protein (10–12 kDa), which are required for entry of" exact="infectious" post="virions into target cells. The virion also contains the"/>
  <result pre="virion also contains the nucleocapsid (N), capable of binding to" exact="viral" post="genomic RNA, and nsp3, a key component of the"/>
  <result pre="S protein at low pH, leading to fusion of the" exact="viral" post="envelope and phospholipidic membrane of the endosomes resulting in"/>
  <result pre="phospholipidic membrane of the endosomes resulting in release of the" exact="viral" post="genome into the cell cytoplasm. Replication then starts and"/>
  <result pre="into the cell cytoplasm. Replication then starts and the positive-strand" exact="viral" post="genomic RNA is transcribed into a negative RNA strand"/>
  <result pre="that is used as a template for the synthesis of" exact="viral" post="mRNA. Synthesis of the negative RNA strand peaks earlier"/>
  <result pre="proteins (NSPs) that assemble into the replicase-transcriptase complex to favour" exact="viral" post="subgenomic mRNA synthesis (see the review by Fehr and"/>
  <result pre="the endoplasmic reticulum and then move to the Golgi compartment." exact="Viral" post="genomic RNA is packaged into the nucleocapsid and then"/>
  <result pre="localises to the trans-Golgi network, plays an essential role during" exact="viral" post="assembly by interacting with the other proteins of the"/>
  <result pre="other proteins of the virus. Following assembly, the newly formed" exact="viral" post="particles are transported to the cell surface in vesicles"/>
  <result pre="for cell surface binding of SARS-CoV-2. If binding of some" exact="viral" post="particles is achieved, chloroquine may modulate the acidification of"/>
  <result pre="the elegant review by Savarino et al. [11]. ERGIC, ER-Golgi" exact="intermediate" post="compartment. Already in 2007, some of us emphasised in"/>
  <result pre="this journal the possibility of using chloroquine to fight orphan" exact="viral" post="infections [10]. The worldwide ongoing trials, including those involving"/>
  <result pre="journal the possibility of using chloroquine to fight orphan viral" exact="infections" post="[10]. The worldwide ongoing trials, including those involving the"/>
  <result pre="role of antimalarial agents in the treatment of SLE and" exact="lupus" post="nephritisNat Rev Nephrol7201171872910.1038/nrneph.2011.15022009248 7RaoultD.DrancourtM.VestrisG.Bactericidal effect of doxycycline associated with"/>
  <result pre="on Coxiella burnetii in P388D1 cellsAntimicrob Agents Chemother3419901512151410.1128/aac.34.8.15122221859 8RaoultD.HoupikianP.TissotD.H.RissJ.M.Arditi-DjianeJ.BrouquiP.Treatment of" exact="Q fever" post="endocarditis: comparison of 2 regimens containing doxycycline and ofloxacin"/>
  <result pre="chloroquine and its hydroxyl analogue to face bacterial, fungal and" exact="viral infection" post="in the 21st centuryInt J Antimicrob Agents30200729730817629679 11SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of"/>
  <result pre="and its hydroxyl analogue to face bacterial, fungal and viral" exact="infection" post="in the 21st centuryInt J Antimicrob Agents30200729730817629679 11SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of"/>
  <result pre="the 21st centuryInt J Antimicrob Agents30200729730817629679 11SavarinoA.BoelaertJ.R.CassoneA.MajoriG.CaudaR.Effects of chloroquine on" exact="viral" post="infections: an old drug against today's diseases?Lancet Infect Dis3200372272714592603"/>
  <result pre="coronavirus in Wuhan, ChinaLancet395202049750610.1016/S0140-6736(20)30183-531986264 14ZhuN.ZhangD.WangW.LiX.YangB.SongJ.A novel coronavirus from patients with" exact="pneumonia" post="in China, 2019N Engl J Med382202072773331978945 15Zhou P., Yang"/>
  <result pre="al. Discovery of a novel coronavirus associated with the recent" exact="pneumonia" post="outbreak in humans and its potential bat origin. bioRxiv2020"/>
  <result pre="origin. bioRxiv2020 Jan 23. doi:10.1101/2020.01.22.914952. 16TsiangH.SupertiF.Ammonium chloride and chloroquine inhibit" exact="rabies" post="virus infection in neuroblastoma cellsArch Virol8119843773826148053 17KronenbergerP.VrijsenR.BoeyéA.Chloroquine induces empty"/>
  <result pre="bioRxiv2020 Jan 23. doi:10.1101/2020.01.22.914952. 16TsiangH.SupertiF.Ammonium chloride and chloroquine inhibit rabies" exact="virus infection" post="in neuroblastoma cellsArch Virol8119843773826148053 17KronenbergerP.VrijsenR.BoeyéA.Chloroquine induces empty capsid formation"/>
  <result pre="Jan 23. doi:10.1101/2020.01.22.914952. 16TsiangH.SupertiF.Ammonium chloride and chloroquine inhibit rabies virus" exact="infection" post="in neuroblastoma cellsArch Virol8119843773826148053 17KronenbergerP.VrijsenR.BoeyéA.Chloroquine induces empty capsid formation"/>
  <result pre="doi:10.1101/2020.01.22.914952. 16TsiangH.SupertiF.Ammonium chloride and chloroquine inhibit rabies virus infection in" exact="neuroblastoma" post="cellsArch Virol8119843773826148053 17KronenbergerP.VrijsenR.BoeyéA.Chloroquine induces empty capsid formation during poliovirus"/>
  <result pre="empty capsid formation during poliovirus eclipseJ Virol651991700870111658391 18TsaiW.P.NaraP.L.KungH.F.OroszlanS.Inhibition of human" exact="immunodeficiency" post="virus infectivity by chloroquineAIDS Res Hum Retroviruses6199048148910.1089/aid.1990.6.4811692728 19SavarinoA.GenneroL.SperberK.BoelaertJ.R.The anti-HIV-1"/>
  <result pre="chloroquineJ Clin Virol20200113113511166661 20RomanelliF.SmithK.M.HovenA.D.Chloroquine and hydroxychloroquine as inhibitors of human" exact="immunodeficiency" post="virus (HIV-1) activityCurr Pharm Des1020042643264815320751 21SupertiF.SegantiL.OrsiW.DiviziaM.GabrieliR.PanaA.The effect of lipophilic"/>
  <result pre="Des1020042643264815320751 21SupertiF.SegantiL.OrsiW.DiviziaM.GabrieliR.PanaA.The effect of lipophilic amines on the growth of" exact="hepatitis" post="A virus in Frp/3 cellsArch Virol96198728929610.1007/bf013209702821967 22BishopN.E.Examination of potential"/>
  <result pre="virus in Frp/3 cellsArch Virol96198728929610.1007/bf013209702821967 22BishopN.E.Examination of potential inhibitors of" exact="hepatitis" post="A virus uncoatingIntervirology41199826127110325536 23MizuiT.YamashinaS.TanidaI.TakeiY.UenoT.SakamotoN.Inhibition of hepatitis C virus replication"/>
  <result pre="of potential inhibitors of hepatitis A virus uncoatingIntervirology41199826127110325536 23MizuiT.YamashinaS.TanidaI.TakeiY.UenoT.SakamotoN.Inhibition of" exact="hepatitis" post="C virus replication by chloroquine targeting virus-associated autophagyJ Gastroenterol45201019520319760134"/>
  <result pre="Infect Dis11201167768321550310 28YanY.ZouZ.SunY.LiX.XuK.F.WeiY.Anti-malaria drug chloroquine is highly effective in treating" exact="avian influenza" post="A H5N1 virus infection in an animal modelCell Res23201330030210.1038/cr.2012.16523208422"/>
  <result pre="chloroquine is highly effective in treating avian influenza A H5N1" exact="virus infection" post="in an animal modelCell Res23201330030210.1038/cr.2012.16523208422 29De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On Chikungunya acute"/>
  <result pre="is highly effective in treating avian influenza A H5N1 virus" exact="infection" post="in an animal modelCell Res23201330030210.1038/cr.2012.16523208422 29De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On Chikungunya acute"/>
  <result pre="virus infection in an animal modelCell Res23201330030210.1038/cr.2012.16523208422 29De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On Chikungunya" exact="acute" post="infection and chloroquine treatmentVector Borne Zoonotic Dis8200883784010.1089/vbz.2008.004918620511 30KhanM.SanthoshS.R.TiwariM.Lakshmana RaoP.V.ParidaM.Assessment"/>
  <result pre="infection in an animal modelCell Res23201330030210.1038/cr.2012.16523208422 29De LamballerieX.BoissonV.ReynierJ.C.EnaultS.CharrelR.N.FlahaultA.On Chikungunya acute" exact="infection" post="and chloroquine treatmentVector Borne Zoonotic Dis8200883784010.1089/vbz.2008.004918620511 30KhanM.SanthoshS.R.TiwariM.Lakshmana RaoP.V.ParidaM.Assessment of"/>
  <result pre="against Chikungunya virus in Vero cellsJ Med Virol82201081782420336760 31DeloguI.de LamballerieX.Chikungunya" exact="disease" post="and chloroquine treatmentJ Med Virol8320111058105921503920 32RandolphV.B.WinklerG.StollarV.Acidotropic amines inhibit proteolytic"/>
  <result pre="U937 cellsMicrobiol Immunol58201431832624773578 34DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.Chloroquine, an endocytosis blocking agent, inhibits Zika" exact="virus infection" post="in different cell modelsViruses82016E32210.3390/v812032227916837 35GlushakovaS.E.LukashevichI.S.Early events in arenavirus replication"/>
  <result pre="cellsMicrobiol Immunol58201431832624773578 34DelvecchioR.HigaL.M.PezzutoP.ValadaoA.L.GarcezP.P.MonteiroF.L.Chloroquine, an endocytosis blocking agent, inhibits Zika virus" exact="infection" post="in different cell modelsViruses82016E32210.3390/v812032227916837 35GlushakovaS.E.LukashevichI.S.Early events in arenavirus replication"/>
  <result pre="Ebola virus replication in vitro but failed to protect against" exact="infection" post="and disease in the in vivo guinea pig modelJ"/>
  <result pre="replication in vitro but failed to protect against infection and" exact="disease" post="in the in vivo guinea pig modelJ Gen Virol9620153484349226459826"/>
  <result pre="the in vivo guinea pig modelJ Gen Virol9620153484349226459826 40KouroumalisE.A.KoskinasJ.Treatment of" exact="chronic" post="active hepatitis B (CAH B) with chloroquine: a preliminary"/>
  <result pre="vivo guinea pig modelJ Gen Virol9620153484349226459826 40KouroumalisE.A.KoskinasJ.Treatment of chronic active" exact="hepatitis" post="B (CAH B) with chloroquine: a preliminary reportAnn Acad"/>
  <result pre="a preliminary reportAnn Acad Med Singapore1519861491523752892 41KoyamaA.H.UchidaT.Inhibition of multiplication of" exact="herpes" post="simplex virus type 1 by ammonium chloride and chloroquineVirology13819843323356093369"/>
  <result pre="Acad Med Singapore1519861491523752892 41KoyamaA.H.UchidaT.Inhibition of multiplication of herpes simplex virus" exact="type 1" post="by ammonium chloride and chloroquineVirology13819843323356093369 42KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of"/>
  <result pre="chloroquineVirology13819843323356093369 42KeyaertsE.LiS.VijgenL.RysmanE.VerbeeckJ.Van RanstM.Antiviral activity of chloroquine against human coronavirus OC43" exact="infection" post="in newborn miceAntimicrob Agents Chemother5320093416342119506054 43BlauD.HolmesK.Human coronavirus HCoV-229E enters"/>
  <result pre="(coronaviruses and arteriviruses)2001KluwerNew York, NY193197 44KonoM.TatsumiK.ImaiA.M.SaitoK.KuriyamaT.ShirasawaH.Inhibition of human coronavirus 229E" exact="infection" post="in human epithelial lung cells (L132) by chloroquine: involvement"/>
  <result pre="York, NY193197 44KonoM.TatsumiK.ImaiA.M.SaitoK.KuriyamaT.ShirasawaH.Inhibition of human coronavirus 229E infection in human" exact="epithelial" post="lung cells (L132) by chloroquine: involvement of p38 MAPK"/>
  <result pre="FDA-approved compound library identifies four small-molecule inhibitors of Middle East" exact="respiratory" post="syndrome coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488410.1128/AAC.03011-1424841269 47MoY.FisherD.A"/>
  <result pre="compound library identifies four small-molecule inhibitors of Middle East respiratory" exact="syndrome" post="coronavirus replication in cell cultureAntimicrob Agents Chemother5820144875488410.1128/AAC.03011-1424841269 47MoY.FisherD.A review"/>
  <result pre="Agents Chemother5820144875488410.1128/AAC.03011-1424841269 47MoY.FisherD.A review of treatment modalities for Middle East" exact="respiratory" post="syndromeJ Antimicrob Chemother7120163340335027585965 48BurkardC.VerheijeM.H.WichtO.van KasterenS.I.van KuppeveldF.J.HaagmansB.L.Coronavirus cell entry occurs"/>
  <result pre="phosphate has shown apparent efficacy in treatment of COVID-19 associated" exact="pneumonia" post="in clinical studiesBiosci TrendsFeb 202010.5582/bst.2020.01047[Epub ahead of print] 51collab:"/>
  <result pre="pneumoniaExpert consensus on chloroquine phosphate for the treatment of novel" exact="coronavirus pneumonia" post="[in Chinese]Zhonghua Jie He He Hu Xi Za Zhi432020E01910.3760/cma.j.issn.1001-0939.2020.001932075365"/>
  <result pre="consensus on chloroquine phosphate for the treatment of novel coronavirus" exact="pneumonia" post="[in Chinese]Zhonghua Jie He He Hu Xi Za Zhi432020E01910.3760/cma.j.issn.1001-0939.2020.001932075365"/>
  <result pre="Za Zhi432020E01910.3760/cma.j.issn.1001-0939.2020.001932075365 52BernsteinH.N.Ocular safety of hydroxychloroquineAnn Ophthalmol2319912922961952638 53RatliffN.B.EstesM.L.MylesJ.L.ShireyE.K.McMahonJ.T.Diagnosis of chloroquine" exact="cardiomyopathy" post="by endomyocardial biopsyN Engl J Med31619871911933796692 54CuberoG.J.Rodriguez RegueroJ.J.Rojo OrtegaJ.M.Restrictive"/>
  <result pre="cardiomyopathy by endomyocardial biopsyN Engl J Med31619871911933796692 54CuberoG.J.Rodriguez RegueroJ.J.Rojo OrtegaJ.M.Restrictive" exact="cardiomyopathy" post="caused by chloroquineBr Heart J6919934514528518071 55HarrisonC.Coronavirus puts drug repurposing"/>
  <result pre="Engl J Med31619871911933796692 54CuberoG.J.Rodriguez RegueroJ.J.Rojo OrtegaJ.M.Restrictive cardiomyopathy caused by chloroquineBr" exact="Heart" post="J6919934514528518071 55HarrisonC.Coronavirus puts drug repurposing on the fast trackNature"/>
  <result pre="eye?Lancet Infect Dis5200518418815766653 59VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS" exact="coronavirus infection" post="and spreadVirol J220056910.1186/1743-422X-2-6916115318 60TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A randomized controlled trial of chloroquine"/>
  <result pre="Infect Dis5200518418815766653 59VincentM.J.BergeronE.BenjannetS.EricksonB.R.RollinP.E.KsiazekT.G.Chloroquine is a potent inhibitor of SARS coronavirus" exact="infection" post="and spreadVirol J220056910.1186/1743-422X-2-6916115318 60TricouV.MinhN.N.VanT.P.LeeS.J.FarrarJ.WillsB.A randomized controlled trial of chloroquine"/>
  <result pre="into Aedes albopictus cellsInfect Genet Evol1220121275128110.1016/j.meegid.2012.02.00322386853 62YangZ.Y.HuangY.GaneshL.LeungK.KongW.P.SchwartzO.pH-dependent entry of severe" exact="acute" post="respiratory syndrome coronavirus is mediated by the spike glycoprotein"/>
  <result pre="Aedes albopictus cellsInfect Genet Evol1220121275128110.1016/j.meegid.2012.02.00322386853 62YangZ.Y.HuangY.GaneshL.LeungK.KongW.P.SchwartzO.pH-dependent entry of severe acute" exact="respiratory" post="syndrome coronavirus is mediated by the spike glycoprotein and"/>
  <result pre="albopictus cellsInfect Genet Evol1220121275128110.1016/j.meegid.2012.02.00322386853 62YangZ.Y.HuangY.GaneshL.LeungK.KongW.P.SchwartzO.pH-dependent entry of severe acute respiratory" exact="syndrome" post="coronavirus is mediated by the spike glycoprotein and enhanced"/>
  <result pre="caveolae-independent endocytic pathwayCell Res18200829030110.1038/cr.2008.1518227861 64CassellS.EdwardsJ.BrownD.T.Effects of lysosomotropic weak bases on" exact="infection" post="of BHK-21 cells by Sindbis virusJ Virol5219848578646492263 65SavarinoA.LuciaM.B.RastrelliE.RutellaS.GolottaC.MorraE.Anti-HIV effects"/>
  <result pre="by Sindbis virusJ Virol5219848578646492263 65SavarinoA.LuciaM.B.RastrelliE.RutellaS.GolottaC.MorraE.Anti-HIV effects of chloroquine: inhibition of" exact="viral" post="particle glycosylation and synergism with protease inhibitorsJ Acquir Immune"/>
  <result pre="synergism with protease inhibitorsJ Acquir Immune Defic Syndr351996223232 66HarleyC.A.DasguptaA.WilsonD.W.Characterization of" exact="herpes" post="simplex virus-containing organelles by subcellular fractionation: role for organelle"/>
  <result pre="by subcellular fractionation: role for organelle acidification in assembly of" exact="infectious" post="particlesJ Virol7520011236125111152497 67KlumpermanJ.LockerJ.K.MeijerA.HorzinekM.C.GeuzeH.J.RottierP.J.Coronavirus M proteins accumulate in the Golgi"/>
  <result pre="is required for triggering NF-κB activation upon interaction of human" exact="immunodeficiency" post="virus type 1 envelope glycoprotein gp120 with cell surface"/>
  <result pre="for triggering NF-κB activation upon interaction of human immunodeficiency virus" exact="type 1" post="envelope glycoprotein gp120 with cell surface CD4J Virol721998620762149621091 74FuldH.HorwichL.Treatment"/>
  <result pre="envelope glycoprotein gp120 with cell surface CD4J Virol721998620762149621091 74FuldH.HorwichL.Treatment of" exact="rheumatoid arthritis" post="with chloroquineBr Med J1519581199120110.1136/bmj.2.5106.1199 75MackenzieA.H.Antimalarial drugs for rheumatoid arthritisAm"/>
  <result pre="glycoprotein gp120 with cell surface CD4J Virol721998620762149621091 74FuldH.HorwichL.Treatment of rheumatoid" exact="arthritis" post="with chloroquineBr Med J1519581199120110.1136/bmj.2.5106.1199 75MackenzieA.H.Antimalarial drugs for rheumatoid arthritisAm"/>
  <result pre="Treat Options Rheumatol2201611210.1007/s40674-016-0036-9 77WozniackaA.LesiakA.NarbuttJ.McCauliffeD.P.Sysa-JedrzejowskaA.Chloroquine treatment influences proinflammatory cytokine levels in" exact="systemic" post="lupus erythematosus patientsLupus15200626827516761500 78SharmaO.P.Effectiveness of chloroquine and hydroxychloroquine in"/>
  <result pre="Options Rheumatol2201611210.1007/s40674-016-0036-9 77WozniackaA.LesiakA.NarbuttJ.McCauliffeD.P.Sysa-JedrzejowskaA.Chloroquine treatment influences proinflammatory cytokine levels in systemic" exact="lupus erythematosus" post="patientsLupus15200626827516761500 78SharmaO.P.Effectiveness of chloroquine and hydroxychloroquine in treating selected"/>
  <result pre="78SharmaO.P.Effectiveness of chloroquine and hydroxychloroquine in treating selected patients with" exact="sarcoidosis" post="with neurological involvementArch Neurol551998124812549740120 79JangC.H.ChoiJ.H.ByunM.S.JueD.M.Chloroquine inhibits production of TNF-α,"/>
  <result pre="affected by disruption of iron metabolismImmunology8019931271338244453 81JeongJ.Y.JueD.M.Chloroquine inhibits processing of" exact="tumor" post="necrosis factor in lipopolysaccharide-stimulated RAW 264.7 macrophagesJ Immunol1581997490149079144507 82ZhuX.ErtelW.AyalaA.MorrisonM.H.PerrinM.M.ChaudryI.H.Chloroquine"/>
  <result pre="human coronavirus OC43Immunol Invest221993951038505072 94ZhaoX.GuoF.LiuF.CuconatiA.ChangJ.BlockT.M.Interferon induction of IFITM proteins promotes" exact="infection" post="by human coronavirus OC43Proc Natl Acad Sci U S"/>
  <result pre="HKU1 spike-mediated infectionJ Virol8320091026103518987136 98MilletJ.K.WhittakerG.R.Host cell entry of Middle East" exact="respiratory" post="syndrome coronavirus after two-step, furin-mediated activation of the spike"/>
  <result pre="spike-mediated infectionJ Virol8320091026103518987136 98MilletJ.K.WhittakerG.R.Host cell entry of Middle East respiratory" exact="syndrome" post="coronavirus after two-step, furin-mediated activation of the spike proteinProc"/>
  <result pre="bioRxiv2020 Jan 26. doi:10.1101/2020.01.26.919985. 100GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.Evidence that TMPRSS2 activates the severe" exact="acute" post="respiratory syndrome coronavirus spike protein for membrane fusion and"/>
  <result pre="Jan 26. doi:10.1101/2020.01.26.919985. 100GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.Evidence that TMPRSS2 activates the severe acute" exact="respiratory" post="syndrome coronavirus spike protein for membrane fusion and reduces"/>
  <result pre="26. doi:10.1101/2020.01.26.919985. 100GlowackaI.BertramS.MüllerM.A.AllenP.SoilleuxE.PfefferleS.Evidence that TMPRSS2 activates the severe acute respiratory" exact="syndrome" post="coronavirus spike protein for membrane fusion and reduces viral"/>
  <result pre="respiratory syndrome coronavirus spike protein for membrane fusion and reduces" exact="viral" post="control by the humoral immune responseJ Virol8520114122413421325420 101FehrA.R.PerlmanS.Coronaviruses: an"/>
  <result pre="(ANR), including the ‘Programme d'investissement d'avenir’ under the reference Méditerranée" exact="Infection" post="10-1AHU-03. Competing interests: None declared. Ethical approval: Not required."/>
 </snippets>
</snippetsTree>
